|
| At Ironwood, patients influence our drugmaking process, helping us to understand and address their needs. Our internal discovery and in-licensing strategies are driven by conversations with physicians about their most difficult-to-treat patients. We seek creative ways to understand the impact of disease on patients: our office décor includes patient-created art, and our scientists have been known to simulate participation in clinical trials so they can better connect with the patient experience.
The idea of how to meet the needs of a patient, the spark that gets a new program off the ground, can come from anyone at Ironwood. Internally, we have a new idea generation process that taps into the entire research organization. We also leverage the talent of our internal scientific team to help us identify external opportunities by working in a highly integrated manner with our in-licensing team.
Once we find a program to advance, we take a disciplined approach to R&D that emphasizes data-driven decision making, clearly defined go/no go criteria and prioritization of programs at all stages to drive forward the most promising programs. Through application of this method, and through great science, we believe we increase the likelihood of keeping our efforts trained on those activities most likely to yield important new medicines. Indeed, our FDA- and EMA- approved drug was the result of just such a process, and we strive to replicate this success as we enhance our pipeline.
|
